CAPR Wutah pendapatan triwulanan Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. (CAPR) - logo korporat

Anticipation of the registration application for the primary Duchenne muscular dystrophy drug is creating positive momentum, and GURU.Markets data informs this chart, where the QoQ revenue growth rate reaches 0.00. The business foundation of Capricor Therapeutics (CAPR) relies on a team of geneticists developing cell therapy and cost optimization through the outsourcing of production to third-party contractors.

Capricor (CAPR) - Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 20.11.2026

Ringkesan rincian data analitis Capricor Therapeutics (CAPR)

- kuotasi saiki lan rata-rata prakiraan nilai:
Ringkesan analisis perusahaan:CAPR - Capricor
Produk sing diprodhuksi Capricor

The resilience of Capricor Therapeutics (CAPR) is based on the synergy between highly qualified scientists and innovations in the field of cardiac cell therapy. By analyzing the quarterly growth of total revenue, an investor can see the real efficiency of commercializing these developments. This metric measures the rate of change in sales within the daily trend, excluding one-time anomalies to assess market conditions. The steady growth of this indicator confirms the fundamental value of the assets and justifies the fair value of the business.